Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Maraviroc (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms MARACOVID
- 24 Feb 2022 Status changed from recruiting to discontinued.
- 07 Jul 2020 Status changed from not yet recruiting to recruiting.
- 24 Jun 2020 New trial record